What Does Pulmonx (LUNG) Do? - Stock Price Outlook, Earnings, Market Cap, Related Stocks, and Headquarters Summary
Pulmonx is the leading US provider of non-invasive treatment solutions for severe emphysema, pursuing market expansion and an earnings turnaround through its proprietary Zephyr Valve technology and the new AeriSeal pipeline.
Subscribe🏢 What kind of company is Pulmonx?
Pulmonx Corp (LUNG) was founded in 1996 and is headquartered in Redwood City, California, where it operates as a leader in lung disease treatment solutions. The company's core business is the 'Zephyr Valve' system, which blocks damaged areas of the lung to help healthy regions expand. The Zephyr Valve is the first endobronchial lung volume reduction valve to receive the FDA's 'Breakthrough Device' designation, and it has been used to treat tens of thousands of patients worldwide, establishing itself as the standard of care for severe emphysema. In addition, the 'Chartis®' lung assessment system enables more precise procedures, providing optimized treatment pathways for individual patients.
💰 How does it make money?
| Business Segment | Revenue Mix | Description |
|---|---|---|
| Zephyr Valve and Disposables (Product) | ~94% | Revenue from sales of the Zephyr Valve system and single-use catheters (core revenue source) |
| Diagnostic and Other Services | ~6% | Revenue from sales of the Chartis system and hospital education support |
Driven by solid global demand, Pulmonx posted revenue of $90.5 million for fiscal year 2025, representing year-over-year growth of approximately 8%. The company maintains a high gross margin above 74% and holds a robust cash position of approximately $69.8 million, which it is channeling into strengthening its US sales organization and funding new clinical trials. Its recent annual total revenue is approximately $87.4M.
📐 Market Cap and Company Scale
The market capitalization stands at $79.5M, which is about About 0% the size of Samsung Electronics' market cap. The company has 296 people employees.
Pulmonx's market capitalization is approximately $79.5M, roughly About 0% the size of Samsung Electronics' market cap. Under the leadership of CEO Glen French, the management team is collaborating with major medical centers worldwide to reinforce its dominance in the rapidly growing severe lung disease market.
📈 Pulmonx Outlook and Share Price Trend
1-Year Price Performance
Analyst Consensus
52-Week Price RangeThe key growth drivers ahead for LUNG are the commercialization of the 'AeriSeal' system and stronger US sales execution. Through the ongoing 'CONVERT II' global clinical trial, the company plans to extend its treatment reach to patient populations previously ineligible for the Zephyr Valve procedure, which is expected to dramatically expand its market potential. The stabilization of the -3.4% metric, combined with the recent announcement of a meaningful resumption of sales in the Chinese market, will serve as the primary catalyst for future share price appreciation. The company's long-term goal is to evolve into an 'integrated lung health platform' spanning the full continuum from diagnosis to treatment of lung disease.
⚔️ Core Competitive Strengths and Risks
The company possesses uniquely FDA-approved technology in the emphysema treatment field and is accelerating the development of a new pipeline to expand its addressable patient population.
💪 Core Competitive Strengths
⚠️ Core Risks
Competitors and Related Stocks (Beneficiaries)
Key competitors include Olympus (OCPNY), a leader in the bronchoscopy field, and Merit Medical (MMSI), a leader in spinal and soft-tissue treatment devices. In the lung disease solution space, the company also competes with Boston Scientific (BSX) and Teleflex (TFX) for technological superiority and hospital contracts.
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
 OM | Outset Medical Inc | $3.27 | -1.2% | $61.4M | - | 0.6 | -59.17% | - |
 HYPR | Hyperfine Inc | $0.78 | -1.0% | $83.1M | - | 2.3 | -96.97% | - |
 ECOR | ElectroCore Inc | $9.19 | +2.2% | $82.8M | - | - | -478.7% | - |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| BSX | Boston Scientific Corp | $43.10 | -4.1% | $62.5B | 17.5 | 2.5 | 15.52% | - |
| MDT | Medtronic Plc | $91.62 | -0.3% | $117.2B | 22.6 | 2.3 | 10.66% | 3.16% |
✅ Investor Checkpoints
Here are three key checkpoints every Pulmonx investor should monitor.
| Checkpoint | What to Verify | Current Status |
|---|---|---|
| 🧬 CONVERT II Clinical Trial Enrollment | Monitor the progress of the pivotal trial determining the success of the AeriSeal system, along with the schedule for data releases. | Caution |
| 📈 US Quarterly Revenue Growth | Watch whether the tangible performance of the US sales team following the organizational restructuring translates into a revenue rebound. | Stable |
| 🇨🇳 Resumption of China Market Supply | Track the regulatory certification renewal in China and the actual resumption of shipments, scheduled for the second half of 2026. | Neutral |
Given the characteristics of the medical device sector, share price volatility can be significant depending on clinical outcomes or regulatory policy changes, and the achievement of earnings guidance should be monitored closely on a quarterly basis.
Pulmonx is a company that delivers the 'freedom to breathe' through technology. Once the results of this painful restructuring begin to show up in the numbers, the stock is poised for a major re-rating as a powerful leader in the lung disease market.
Check Pulmonx's real-time quotes, technical indicators, and peer comparisons at a glance on US Stock Today's real-time dashboard.
Subscribe Today's 5 AI picks, all free